Winner of the Minister of Trade, Industry and Energy Award in the Biohealth Sector
Linksolution announced on December 1 that it has been selected as an outstanding research and development (R&D) company in the biohealth sector at the "2025 Bio Industry Day" and received the Minister of Trade, Industry and Energy Award.
The company explained that this recognition was due to its 3D printing-based customized oral pharmaceutical technology, which has been highly evaluated for its technical completeness and industrial applicability in the fields of personalized medicine and precision formulation.
The Ministry of Trade, Industry and Energy selects and awards outstanding companies and researchers every year to strengthen the technological competitiveness of the biohealth industry and promote the commercialization of R&D achievements. This year, Linksolution's 3D printing-based patient-customized tablet manufacturing technology stood out in the outstanding company category. The technology, which allows for precise control of drug dosage and release patterns according to patient characteristics, was highly praised for integrating fine dosage design, multi-layer structures, and release control functions into a single platform-capabilities that are difficult to achieve with conventional manufacturing methods.
Linksolution has developed its own dedicated 3D printer capable of stably layering and printing pharmaceutical polymers and has established a pilot production process to verify the technology demonstration stage. In addition, its joint research with Dong-A Pharmaceutical to prove the feasibility of real-world application was also positively evaluated.
The core of Linksolution's 3D printing tablet manufacturing technology is its ability to precisely design the required drug potency and dosing patterns for each patient. Because the structure and content of the tablet are digitally controlled, stable dosing design is possible even for sensitive patient groups such as the elderly or children. The technology can also realize multi-layer structures or complex ingredients in a single tablet, reducing the medication burden for patients requiring long-term treatment.
Since the technology enables production of only the required amount at the desired time, it is highly applicable to the development of orphan drugs or pharmaceuticals that require small-batch manufacturing. As the trend toward personalized treatment rapidly expands in medical settings, the industry is paying attention to the fact that this technology can cover areas that were previously difficult to address with conventional manufacturing processes.
Overseas, 3D-printed pharmaceuticals have already entered the commercialization stage. A representative example is "Spritam" by Aprecia in the United States, which received approval from the U.S. Food and Drug Administration (FDA). The global market is also expected to grow to 1 billion dollars by 2035. This provides a favorable environment for Linksolution to expand its overseas technology partnerships and customized formulation development business in the future.
A Linksolution representative stated, "This award means that Linksolution's fundamental technological capabilities in equipment, processes, and materials have been recognized as competitive in the biohealth industry." He continued, "We will accelerate the commercialization of customized oral pharmaceuticals through stronger collaboration with domestic pharmaceutical companies, and in the global market, we aim to set a new standard for 3D printing-based formulation technology."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
